Evaluation of the product based on Recaldent technology in the treatment of dentin hypersensitivity.
OBJECTIVE
The aim of the study was to evaluate the efficiency of GC Tooth Mousse in the treatment of patients with dentin hypersensitivity caused by various factors.


METHODS
The evaluation was carried out on 101 teeth with dentin hypersensitivity in 13 patients. Patients with gingival recession and exposed dental necks and those with non-carious lesions at the initial stage were selected. The initial examination was to evaluate the intensity of pain inducted by a stream of the air syringe and by probing the tooth surface. It was repeated directly after the preparation application, after 15 minutes, after 1 and 4 weeks.


RESULTS
After the medicine application, the number of teeth reacting with strong or extremely strong pain decreased (from almost 80% to 37.62%). The percentage of teeth reacting with mild pain increased by 15% and the number of teeth which did not react to the cold air stream also increased by 27.72%. The values after 15 minutes were similar. A week later, the percentage of teeth with very strong pain was elevated and so was the percentage of medium pain. On the other hand, the number of teeth without pain and with mild pain decreased twice. After one month the percentage distribution was close to the results obtained after 7 days.


CONCLUSIONS
1. GC Tooth Mousse preparation, based on Recaldent technology reveals insufficient effectiveness and short-term therapeutic effect in treating hypersensitivity of dentine. 2. It seems that soothing the pain by GC Tooth Mousse should be regarded rather as an additional remineralizing effect of the medicine.
Kowalczyk
A
A
Department of Dentistry Propaedeutics, Medical University of Białystok, Poland.
Botuliński
B
B
Jaworska
M
M
Kierklo
A
A
Pawińska
M
M
Dabrowska
E
E
D000328:Adult; D002364:Caseins / Q000008:administration & dosage*; D003807:Dentin Sensitivity / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017211:Treatment Failure
D002364:Caseins; C447032:casein phosphopeptide-amorphous calcium phosphate nanocomplex